CTLT

TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger – NS, CTLT, SCX, EVBG

Retrieved on: 
Thursday, April 4, 2024
Empire, NuStar Energy, SCX, Everbridge, Sale, Catalent, CTLT, Thoma Bravo, NS, Security (finance)

Under the terms of the agreement, NS shareholders are expected to receive 0.4 shares of Sunoco per share they own.

Key Points: 
  • Under the terms of the agreement, NS shareholders are expected to receive 0.4 shares of Sunoco per share they own.
  • Under the terms of the agreement, CTLT shareholders will receive $63.50 in cash per share they own.
  • Under the terms of the agreement, EVBG shareholders will receive $28.60 in cash per share they own.
  • Before you hire a law firm, you should talk to a lawyer and ask:
    Do you file class actions and go to Court?

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. - CTLT

Retrieved on: 
Thursday, March 7, 2024
Pomerantz, FDA, News, Syringe, Novo Nordisk, Safety, Food and Drug Administration, LLP, Catalent, Freedom, CTLT

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT).

Key Points: 
  • NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT).
  • The investigation concerns whether Catalent and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • As part of the transaction, Novo Nordisk will acquire three Catalent manufacturing facilities, including a plant located in Bloomington, Indiana.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Catalent, Inc. by Novo Holdings

Retrieved on: 
Friday, March 1, 2024
Acquisition, Person, Telephone, Sale, Novo Nordisk, LLP, Catalent, CTLT, Holding company

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Catalent by Novo Holdings (“Novo”).

Key Points: 
  • You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Catalent by Novo Holdings (“Novo”).
  • As a result of the merger, Catalent stockholders will receive $63.50 per share in cash.
  • Novo is affiliated with Novo Nordisk, and Catalent is the main manufacturing partner for Novo Nordisk’s blockbuster weight loss drug, Wegovy.
  • Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, California, and Washington, D.C.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. - CTLT

Retrieved on: 
Wednesday, February 28, 2024
Pomerantz, FDA, News, Syringe, Novo Nordisk, Safety, Food and Drug Administration, LLP, Catalent, Freedom, CTLT

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT).

Key Points: 
  • NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT).
  • The investigation concerns whether Catalent and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • As part of the transaction, Novo Nordisk will acquire three Catalent manufacturing facilities, including a plant located in Bloomington, Indiana.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Catalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment

Retrieved on: 
Thursday, March 7, 2024
Environment, Medical Devices, Climate Change, Professional Services, Sustainability, Biotechnology, DEI (Diversity, Equity and Inclusion), Pharmaceutical, Health, Environmental, Social and Governance (ESG), Workplace, Education, STEM, Targets, Safety, Corporate social responsibility, Climate change, Patient, CTLT, Science Based Targets initiative, Science, Community, Corporation, GHG, Management

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, has today published its fiscal 2023 Corporate Responsibility Report, highlighting positive progress across every pillar of Catalent’s corporate responsibility strategy – People, Environment, and Community.

Key Points: 
  • Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, has today published its fiscal 2023 Corporate Responsibility Report, highlighting positive progress across every pillar of Catalent’s corporate responsibility strategy – People, Environment, and Community.
  • The report also outlines the company’s future commitments as it progresses its mission to help people lead better and healthier lives.
  • One area of significant progress in fiscal 2023 was Catalent’s efforts to reduce its environmental footprint and address the harmful effects of climate change.
  • A key initiative supporting this progress was the implementation of ISO-certified environmental management systems at 24 Catalent locations, which account for more than 70% of Catalent’s overall energy use.

CATALENT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalent, Inc. - CTLT

Retrieved on: 
Friday, February 16, 2024
Class Action Lawsuit, Professional Services, Legal, KSF, Catalent, Sale, CTLT

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Catalent, Inc. (NYSE: CTLT) to Novo Holdings.

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Catalent, Inc. (NYSE: CTLT) to Novo Holdings.
  • Under the terms of the proposed transaction, shareholders of Catalent will receive $63.50 in cash for each share of Catalent that they own.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

Catalent, Inc. Reports Second Quarter Fiscal 2024 Results

Retrieved on: 
Friday, February 9, 2024
Biotechnology, Pharmaceutical, Genetics, Health, Novo, PCH, COVID-19, CTLT, GAAP, Ratio, Biopharmaceutical, Patient

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the second quarter of fiscal 2024, which ended December 31, 2023.

Key Points: 
  • Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the second quarter of fiscal 2024, which ended December 31, 2023.
  • “I am proud of the progress the Catalent team made in our second quarter and our ongoing momentum, including strong non-COVID sequential revenue growth in both the Biologics and PCH segments.
  • EBITDA (loss) from operations(1) was $6 million, a decrease of $258 million from the $264 million reported in the second quarter a year ago.
  • Second quarter fiscal 2024 Adjusted EBITDA(1) was $124 million, or 12.0% of net revenue, compared to $283 million, or 24.6% of net revenue, in the second quarter a year ago.

CTLT Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Catalent, Inc. for Potential Securities Law Violations

Retrieved on: 
Wednesday, February 7, 2024
Wohl, Catalent, News, CTLT, Safety, Freedom, FDA, Syringe, Food, Acquisition, Freedom of information, Novo Nordisk

The plant is among those being acquired by Novo Nordisk in connection with the recently announced acquisition of Catalent by Novo Holdings.

Key Points: 
  • The plant is among those being acquired by Novo Nordisk in connection with the recently announced acquisition of Catalent by Novo Holdings.
  • On February 5, 2024, Catalent announced that it had agreed to be sold to Novo Holdings for $63.50 per share in cash.
  • As part of the transaction, Novo Nordisk will acquire three Catalent manufacturing facilities, including a plant located in Bloomington, Indiana.
  • As a result of the Bloomberg article, Catalent’s stock price dropped 2.27% in trading on February 6, 2024.

CTLT Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Catalent to Novo Holdings

Retrieved on: 
Monday, February 5, 2024
Wohl, Catalent, CTLT, Elliott Investment Management, Seeking Alpha, Sale, Novo Nordisk, Audit

MONSEY, N.Y., Feb. 05, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the price of $63.50 per share in cash for which Catalent, Inc. (NYSE: CTLT) (“Catalent”) has agreed to be sold to Novo Holdings.

Key Points: 
  • MONSEY, N.Y., Feb. 05, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the price of $63.50 per share in cash for which Catalent, Inc. (NYSE: CTLT) (“Catalent”) has agreed to be sold to Novo Holdings.
  • Notably, Novo Holdings is the controlling shareholder of the Novo Group companies (including Novo Nordisk), and Catalent is one of Novo Nordisk’s main manufacturing partners for its popular weight-loss drug Wegovy.
  • On February 5, 2024, Catalent announced that it had agreed to be sold to Novo Holdings for $63.50 per share in cash.
  • “We are investigating whether the Catalent Board of Directors acted in the best interests of Catalent shareholders in approving the sale,” explained Joshua Fruchter, a founding partner of Wohl & Fruchter.

SHAREHOLDER NEWS: Johnson Fistel Investigates Proposed Sale of Catalent; Is $63.50 a Fair Price?

Retrieved on: 
Monday, February 5, 2024
Class Action Lawsuit, Professional Services, Legal, Learning, Sale, Growth, CTLT, LLP, Acquisition

Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Catalent (NYSE:CTLT) breached their fiduciary duties in connection with the proposed sale of the Company to Novo Holdings.

Key Points: 
  • Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Catalent (NYSE:CTLT) breached their fiduciary duties in connection with the proposed sale of the Company to Novo Holdings.
  • You can click on the following link to join this investigation:
    On February 5, 2024, Catalent announced that it had entered a deal to merge with Novo Holdings.
  • Under the terms of the deal, Catalent shareholders will receive $63.50 per share in an all-cash offer.
  • Nationally recognized, Johnson Fistel is investigating whether the proposed deal represents adequate consideration, especially given analysts' projections for future earnings growth.